مباشر

Endpoints NewsBMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus Promega BlogTiny Edits, Big Harvests: How a Massive Mutation Screen Could Transform Crop Engineering PharmaVoiceChina’s biotech rise sparks new US industry alliance FierceBiotechStruggling Liminatus pays $320M in stock for CAR-T biotech InnocsAI Eli LillyLilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling - BioSpace CellScavenger receptor class F member 2 is an intracellular receptor for hepatitis B virus CellHarnessing citizen science to contextualize adaptation mechanism discovery Endpoints NewsLilly’s triple agonist still leads among late-stage obesity assets Eli LillyExperimental Drug Yields Dramatic Weight Loss - The New York Times Eli LillyEli Lilly maintains M&A streak with $202m Engage Bio buyout - Pharmaceutical Technology FierceBiotechInfex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a Thermo FisherThermo Fisher Scientific’s SWOT analysis: stock navigates growth amid strategic shifts - Investing.com

Endpoints News ٢١ مايو ٢٠٢٦

Lilly’s triple agonist still leads among late-stage obesity assets

Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They had better hope...

Many developers of obesity drugs are fond of saying that it’s not a competition to produce the strongest and fastest level of weight loss. They had better hope they’re right, because if it is a ...